Authors

Latest:

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

David C. Metz, MBBCh

Latest:

Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

David C. Metz, MD

Latest:

Dr. Metz on Increasing Incidence of Neuroendocrine Tumors

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.

David C. Portnoy, MD

Latest:

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

David Carbone, MD, PhD

Latest:

Low-Dose CT Screening for Lung Cancer: A New Era in Germany

Experts discuss the recent landmark approval of a national lung cancer screening program in Germany for high-risk individuals. The program, based on the NELSON trial, will use low-dose CT scans for smokers and former smokers aged 50-75 who quit within the last 10 years.

David Cella, PhD

Latest:

Dr. Cella on Patient-Reported Outcomes in a Clinical Setting

Dr. David Cella from Northwestern University Feinberg School of Medicine on Patient-Reported Outcomes in a Clinical Setting

David Cibula, MD

Latest:

Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer

David Cibula, MD, a gynecologic oncologist at the Gynaecologic Center of Charles University, discusses a trial that examined the addition of dendritic cell-based immunotherapy to chemotherapy in patients with relapsed ovarian cancer.

David D. Chang, MD, PhD

Latest:

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

David D. Thiel, MD

Latest:

Dr. Thiel on Protecting Patients and Providers From COVID-19

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

David Delaney, MD

Latest:

Big Data Era Arrives in Clinical Practice Via CancerLinQ Project

This new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.

David E. Avigan, MD

Latest:

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.

David Eagle, MD

Latest:

Dr. David Eagle on Cost-Drivers in Oncology

David Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.

David F. McDermott, MD

Latest:

Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.

David F. McDermott, MD, Dana Farber Harvard Cancer Center

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

David F. McDermott, MD, Harvard Cancer Center

David F. Penson, MD, MPH

Latest:

Dr. Penson on Ongoing Research in Prostate Cancer

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

David F. Penson, MD, MPH, MMHC

Latest:

Dr. Penson on Ongoing Research in Prostate Cancer

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

David G. Maloney, MD, PhD

Latest:

Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive Lymphomas

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

David H. Ilson, MD, PhD

Latest:

Dr. Ilson on the Utility of Zolbetuximab in Claudin-Positive Gastric Cancers

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

David H. Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center